Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 5:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–11 of 11 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 2 Interventional Accepts healthy volunteers

Treating Hyperexcitability in AD With Levetiracetam

NCT03875638
Conditions
Alzheimer Dementia, Alzheimer Disease, Dementia of Alzheimer Type, Mild Cognitive Impairment
Interventions
Levetiracetam, Placebo oral capsule
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
50 Years to 90 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Seizures, Disorder of Fetus or Newborn
Interventions
Low dose levetiracetam, High dose levetiracetam
Drug
Lead sponsor
Richard H. Haas
Other
Eligibility
1 Minute to 14 Days
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
San Diego, California
Conditions
Parkinson Disease Psychosis
Interventions
AGB101
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 3 Interventional Results available

Add on Lacosamide Versus High Dose Monotherapy

NCT01345058
Conditions
Epilepsy
Interventions
lacosamide, levetiracetam
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Hippocampal Overactivity, Dementia
Interventions
AGB101, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Schizophrenia
Interventions
Levetiracetam, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Mild Cognitive Impairment, Prodromal Alzheimer's Disease
Interventions
AGB101, Placebo
Drug
Lead sponsor
AgeneBio
Industry
Eligibility
55 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Focal Onset Seizures
Interventions
JNJ-40411813, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 69 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
Tucson, Arizona • Orlando, Florida • Port Orange, Florida + 4 more
Conditions
Status Epilepticus
Interventions
Levetiracetam (LEV) (60 mg/Kg) + 1 mg/kg Ketamine (KET), Levetiracetam (LEV) (60 mg/Kg) + 3 mg/kg Ketamine (KET), Levetiracetam (LEV) (60 mg/Kg)
Drug
Lead sponsor
University of Virginia
Other
Eligibility
1 Year and older
Enrollment
770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
63
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 38 more
Completed Not applicable Interventional Results available

Seizure Activity in Alzheimer's Disease

NCT01554683
Conditions
Alzheimer's Disease, Seizures
Interventions
Low/High/Placebo Dose Keppra (Levetiracetam)
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
50 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Terminated Not applicable Interventional Results available

Busulfan and Cyclophosphamide Followed By ALLO BMT

NCT01685411
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Allopurinol, Keppra, Busulfan, Cyclophosphamide, Tacrolimus, Mycophenolate mofetil, Allogeneic hematopoietic stem cell transplant, Filgrastim, antithymocyte globulin
Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 44 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota